Pinus pollen allergen (None)

Pinus pollen allergens are proteinaceous components found in the pollen of various pine species, such as Pinus sylvestris and Pinus radiata, which act as triggers for Type I hypersensitivity reactions [1]. These allergens, including profilins (e.g., Pin s 1) and lipid transfer proteins (e.g., Pin s 3), interact with allergen-specific IgE antibodies bound to high-affinity FcεRI receptors on mast cells and basophils [2]. This binding leads to the cross-linking of receptors and the subsequent release of inflammatory mediators like histamine, which cause symptoms of allergic rhinitis, conjunctivitis, and asthma [3]. While pine pollen was historically considered to have low allergenicity due to its large size and low protein content, it is now recognized as a significant cause of seasonal pollinosis in specific geographic regions [2]. Therapeutic strategies include allergen immunotherapy (AIT) for desensitization and the use of biologics like Omalizumab to neutralize IgE antibodies [4]. Monitoring of patient response is typically conducted through skin prick testing or the measurement of serum-specific IgE levels [1]. Citations: [1] WHO/IUIS Allergen Nomenclature Sub-committee (allergen.org); [2] Gastaminza, G., et al. (2009). Clinical & Experimental Allergy; [3] Galli, S. J., & Tsai, M. (2012). Nature Medicine; [4] FDA (2023). Allergenic Extracts - Licensed Products.

Other names

Pine pollen allergenPinus sylvestris pollen allergenPinus radiata pollen allergenConifer pollen allergen

Allergen immunotherapy (AIT) involves the repeated administration of Pinus pollen extracts to shift the immune response from an IgE-mediated Th2 response to a tolerant Th1/Treg response, characterized by increased IgG4 production [3]. Anti-IgE therapy, such as Omalizumab, works by binding to circulating IgE, thereby preventing it from interacting with Pinus pollen allergens and triggering the allergic cascade [4].